Cell surface antigens: Prognostic implication in childhood acute lymphoblastic leukemia
|
|
- Naomi Neal
- 5 years ago
- Views:
Transcription
1 See discussions, stats, and author profiles for this publication at: Cell surface antigens: Prognostic implication in childhood acute lymphoblastic leukemia Article in Blood April 1980 Impact Factor: Source: PubMed CITATIONS 171 READS 45 8 authors, including: Jerome Ritz Harvard Medical School 495 PUBLICATIONS 26,762 CITATIONS SEE PROFILE Available from: Jerome Ritz Retrieved on: 13 May 2016
2 : Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia SE Sallan, J Ritz, J Pesando, R Gelber, C O'Brien, S Hitchcock, F Coral and SF Schlossman Information about reproducing this article in parts or in its entirety may be found online at: Information about ordering reprints may be found online at: Information about subscriptions and ASH membership may be found online at: Blood (print ISSN , online ISSN ), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC Copyright 2011 by The American Society of Hematology; all rights reserved.
3 Cell Surface Antigens: Prognostic Implications in Childhood Acute Lymphoblastic Leukemia By Stephen E. Sallan, Jerome Ritz, John Pesando, Richard Gelber, Carmeline O Brien, Suzanne Hitchcock, Felice Coral, and Stuart F. Schlossman Lymphoblasts from 93 children with acute lymphoblastic leukemia (ALL) were characterized by immunologic cell surface markers. These patients were treated on a single protocol, featuring adriamycin therapy during remission. and have been followed from 2 to 6.5 yr (median 4 yr). Three classes of patients were defined serologically: HTA + Ia - CALLA -. Ia + CALLA + HTA -. and Ia + CALLA - HTA -. Disease-free survival and sites of relapse were assessed within immunologic subsets. Similar to the findings of others, T-cell (HTA + Ia - ) patients fared poorly as compared to non-t-cell (Ia + HTA -) patients (median disease-free survival was 12 and 47 mo. respectively; p = ). The majority of relapses in the HTA+ patients occurred at extramedullary sites. Late testicular relapse was rare among Ia + patients. In addition. the common ALL antigen (CALLA) may identify a relatively favorable subset within the Ia + population. The prognostic value of the immunologic markers was compared with traditional clinical factors. There was much overlap between HTA +. older age. and elevated WBC. However. neither age nor WBC alone were of prognostic significance among the Ia + patients. We conclude that surface markers define both biologic and prognostic characteristics. The course of childhood ALL must be viewed in the context of homogeneous subsets and within particular therapeutic programs. W ITHIN the past 15 yr, many factors have contributed to a marked improvement in the prognosis of childhood acute lymphoblastic leukemia (ALL). Newer chemotherapeutic and support programs have resulted in survival of approximately 40%- 50% of children with ALL for at least 5 yr. 3 Despite these successes, it has become increasingly important to critically evaluate those children who have failed to respond to current treatment regimens. It is possible that unresponsive children with ALL represent subsets of this disease that are biologically distinct and, as such, require different therapeutic strategies. Insight into the heterogeneity of ALL has resulted from recent studies from several laboratories that have identified normal lymphocyte differentiation antigens and receptors on the surfaces of these neoplastic cells. Approximately 20% of children with ALL have lymphoblasts with surface receptors for sheep erythrocytes and T-cell antigens. The remaining 80% of children have lymphoblasts that lack B-cell surface characteristics, such as surface immunoglobulin, but do have Ia-like antigens.59 More importantly, it appears that patients with lymphoblasts of T-cell lineage have a much poorer prognosis than those with a reciprocal subset of non-t-cell lymphoblasts. Earlier studies from this laboratory have demonstrated that three antisera, anti-hta, anti-ia (p23,30), and anti-calla, are particularly useful in defining distinct subsets of ALL cells.7 #{176}HTA antiserum was prepared against a T-cell variant of ALL, and the antiserum reacts only with T-cell ALL cells, normal thymocytes, and circulating T cells. The Ia antiserum was prepared against a glycoprotein complex (p23,30) purified from a human B-cell lymphoblastoid line. Anti-Ia reacts with B cells, B-cell lines, monocytes, and subsets of null cells destined to differentiate into B cells, myeloid cells, or erythrocytes Antisera to the common ALL antigen (CALLA) was prepared against the lymphoblasts of an individual with HTA- Ia+ lymphoblasts. Details of the preparation and characterization of this antisera are reported elsewhere. #{176} In this article, we describe the clinical characteristics and results of therapy of a homogeneously treated group of patients who have been followed for a median of 4 yr and in whom subsets of ALL were defined phenotypically by three cell surface markers: HTA, Ia, and CALLA. MATERIALS AND METHODS The diagnosis of ALL was established by two or more experienced morphologists using previously described criteria. Patients with lymphoma-like disease were included if the bone marrow contained greater than 25% lymphoblasts at the time of diagnosis. One-hundred thirty-seven consecutive children, 20 yr of age and under, presenting to the Sidney Farber Cancer Institute or the Children s Hospital Medical Center with previously untreated ALL were entered on the treatment program between October 1973 and May Informed consent was obtained from parents or guardians before therapy was begun. The results of treatment for this group have been previously reported. The median follow-up for this homogeneously treated group is 4 yr. The presenting clinical characteristics of 93 patients in whom immunologic cell surface marker studies were obtainable are listed in Table I. In the remaining 44 patients, cells could not be obtained for study. Most of these latter From the Divisions of Pediatric Hematology-Oncology and Tumor Immunology, Sidney Farber Cancer Institute; the Children s Hospital Medical Center; and the Departments of Pediatrics and Medicine, Harvard Medical School, Boston, Mass. Supported in part by Grants CA CA 227/9-0!. CA / CA 06270, National Cancer Institute, National Institutes ofhealth, and I-ROJ-CA O1. Submitted August 14, 1979; accepted October Address reprint requests to Stephen E. Sallan, M.D.. 44 Binney Street, Boston, Mass. 021/5. I 980 by Grune & Stratton, Inc /80/ $0I.00/0 Blood. Vol. 55, No. 3 (March),
4 396 SALLAN ET AL. Table 1. Presenting Characteristics of 88 Patients: Evaluation by Cell Surface Markers HTA Total a CALLA CALLA Number of patients Age (yr) Median Number< > Sex male/female 8/3 39/38 1 8/ 1 8 5/2 Mediastinal mass White blood count (per cu mm) Median 93,000 10,800 17,600 3,900 Number>25, HTA patients were Ia and CALLA. and Ia patients were HTA and CALLA or CALLA -. as shown above. Five additional patients were marked. One patient was HTA a CALLA and 4 others were HTA la with 3 of these 4 CALLA (see text). patients were seen during the first year of the treatment program when marker studies and cryopreservation facilities were not readily available. Treatment Regimen Remission induction consisted of vincristine and prednisone. Asparaginase was used to effect early consolidation. Central nervous system prophylaxis consisted of whole brain irradiation using a linear accelerator to 2400 rad/ I 3fx/ 17 days and intrathecal methotrexate given within the same time span. 4 Thereafter, intrathecal methotrexate was administered every 1 8 wk. Treatment in remission involved courses of adriamycin, 6-mercaptopurine, vincristine, and prednisone given every 3 wk. After completion of a total cumulative adriamycin dose of 450 mg/sq m of body surface area, the adriamycin was replaced by parenteral methotrexate for the duration of treatment. Dosages of myelosuppressive agents were adjusted to permit administration of maximum doses. 5 Therapy was electively discontinued after 30 mo of continuous complete remission. Cell Preparation Heparinized bone marrow samples were collected, and mononuclear cells were purified by Ficoll-Hypaque density sedimentation. 6 Isolated mononuclear cells were cryopreserved using standard techniques and stored at - 196#{176}Cwith 5% DMSO and 5% fetal calf serum. In several patients, cells were tested immediately and were not frozen. There was no difference between surface markers of fresh or frozen cells. Cytocentrifuge smears of samples after Ficoll- Hypaque purification were used to verify the predominance of lymphoblasts in all samples subsequently analyzed for surface markers. Preparation of Antisera Rabbit T-cell antisera (HTA) were raised by intravenous injection of E-rosette positive, Ia negative-leukemic cells. HTA was made specific for peripheral blood T cells, thymocytes, and T-cell ALL by absorption with AB erythrocytes, cells from an autologous B-cell line, and with allogeneic chronic lymphocytic leukemia cells. Similar antisera have been made in other laboratories. 7 9 The Ia antigen and rabbit antisera to this antigen have been described in previous Preparation and characterization of antisera to CALLA are a described elsewhere. 0 Briefly, rabbits were immunized by intravenous injections of leukemic cells from a patient with HTA - Ia + ALL. Specificity for CALLA was obtained after absorption with AB erythrocytes, cells from an autologous lymphoblastoid B-cell line, and cells from an allogeneic leukemic T-cell line, CEM.2#{176} Anti-CALLA reacts specifically with cells from 80% of patients with HTA- Ia+ ALL and from some patients with chronic myelogenous leukemia in blast crisis, but does not react with cells from patients with T-cell ALL or acute myeloblastic leukemia, or from leukemic T-cell or lymphoblastoid B-cell lines. Normal peripheral blood lymphocytes and bone marrow cells are also unreactive. The survival curves were plotted according to the method of Kaplan and Meier2 Analysis of the curves was carried out using the log rank statistic.22 A Cox proportional hazard regression model was used for a multivariate analysis of prognostic factors.23 RESULTS With the exception of five patients whose lymphoblasts had unusual surface markers (see below), all HTA+ patients were Ia- CALLA-, and all Ia+ patients were HTA -. Therefore, for purposes of clarity, we will subsequently refer to HTA + Ia - patients only as HTA+, and to HTA- Ia+ patients only as Ia+. The use of anti-calla will be added to the Ia + group whenever necessary. Representative fluorescence-activated cell sorter (FACS-I) printouts plotting fluorescence intensity versus cell number (for 40,000 cells analyzed) are illustrated for three patients with ALL in Fig. 1 : Fig. 1A shows a patient with HTA+ ALL; Fig. lb shows Ia+ ALL; and Fig. 1C shows Ia+ CALLA+ ALL. Of the 93 patients who had bone marrow lymphoblasts characterized at the time of diagnosis, 88 could be divided into one of two classes: HTA + or Ia +. Cells from 43 of the latter patients were available for testing with anti-calla. Presenting characteristics of these 88 patients by immunologic marker are shown in Table 1, and the results of treatment based on immunologic marker are shown in Table 2. Five patients had unusual surface markers. One was HTA+ Ia+ CALLA+. He was a 9-yr-old who presented without a mediastinal mass or elevated WBC (defined herein as >25,000/cu mm). He remains disease-free at 4.5 yr and has been off all chemotherapy for 2 yr. Of the 4 patients who were HTA - Ia -, only 3 had enough cells available to assay for CALLA and all 3 were CALLA-. One patient was a 19-mo-old female who presented without a mediastinal mass or elevated WBC. She failed to enter complete remission and died soon thereafter. Another of these patients was an 1 1-mo-old male who presented without a mediastinal mass but with a WBC of 93,000/cumm. He entered complete remission but was withdrawn from treatment to be taken to a faith healer. The other two children presented without mediastinal masses or elevated WBCs. Both remain disease-free for 1.5 and 3.5 yr. respectively, the latter off treatment for 1 yr.
5 IMMUNE MARKERS IN CHILDHOOD ALL ANTl-HTA.#{149}..ANTI-Io(p23,30) xxxx Normal Rabbit Serum 0000 ANTI-HTA S... ANTI-Ia(p23,30) K M X K Normal Rabbit Sirum U w D z -J w C-) 2 -I -J U C) A FLUORESCENCE INTENSITY B FLUORESCENCE INTENSITY A ANTI-CALLA 0 ANTI-HTA. ANTI-Ia x Normal Rabbit Serum Lu z -J -J Lu C) Fig. 1. (A-C) Indirect immunofluorescence assay of leukemic cells and anti-hta, anti-la, and anti-calla using the fluorescence-activated cell sorter for analysis. Forty-thousand cells were counted in each sample and presented as a histogram of number of cells versus intensity of fluorescence for each antigen. Normal rabbit serum is used as a negative control in each analysis. (A) Leukemic cells are anti-hta positive, anti-la negative. (B) Leukemic cells are anti-hta negative. anti-la positive. (C) Leukemic cells are anti-hta negative. anti-la positive. anti-calla positive. C FLUORESCENCE INTENSITY
6 398 SALLAN ET AL. Table 2. Results of Treatment in 88 Patients: Evaluation by Cell Surfac e Markers HTA Total Ia CALLA CALLA Number evaluable Number complete remissions Withdrawals or remission deaths Duration of remission (See Fig. 3) Relapses Number Bone marrow only Meninges only Marrow and meninges Testes only Testes Testes, and meninges meninges and marrow Three HTA patients were removed from protocol in remission at 1 1 +, and 8+ mo (see text). One la+ CALLA+ patient died in remission at 1 + mo, one Ia + CALLA unknown patient died in remission at 16 + mo, and one Ia + CALLA - patient was lost to follow-up at 1 mo. Patients who were removed from protocol or lost to follow-up are considered incomplete (censored) observations in the life table analyses. Patients who died in remission are considered failures at the time of death. As shown in Table I, the HTA+ group were older, had a male predominance, and most had mediastinal masses and elevated WBCs. As shown in Table 2, 10 of the I I patients entered complete remission. Six of the patients relapsed between 3 and 23 mo, with a median time to relapse of 12 mo (Fig. 2). Primary sites of relapse were the bone marrow in two patients, meninges in one, testes in one, testes and meninges in one, and bone marrow, testes, and meninges in one. Three of the 10 complete remitters were withdrawn from this treatment protocol while in complete remis- Ia sion when it became apparent that HTA+ individuals were responding poorly to the treatment program. Leukemic cells in 10 of the 1 1 HTA+ patients were tested for the formation of E-rosettes, and all were found positive. The 77 children with Ia + lymphoblasts had a median age of 5 yr, an equal male-to-female ratio, and presented without mediastinal masses (Table 1). Seventy-three entered complete remission. Of the 73 complete remitters in the Ia + group, one was lost to followup, one died in remission, and 29 relapsed (Fig. 2). Twenty-four of the relapses were in the bone marrow only and occurred between 9 and 48 mo after entering complete remission. Three patients developed primary meningeal relapses. One child had originally presented with central nervous system involvement, another had received cranial irradiation through inadequate ports, and the third child s nervous system relapse could not be explained. Simultaneous bone marrow and meningeal relapse occurred in one patient 44 mo after entering complete remission. The only testicular relapse occurred in a patient who had been disease-free for 33 mo. Of the children who relapsed, 2 were under age 2 yr at the time of diagnosis, 6 were over age 9 yr. and 1 0 had presented with elevated WBCs. Forty-four of the 73 complete remitters completed 30 mo in remission and have been off chemotherapy for 1-37 mo (median time off treatment is 21 mo); 1 1 of these relapsed after elective cessation of chemotherapy. The difference in diseasefree survival between the HTA + and Ia + patients shown in Fig. 2 is statistically significant using the log rank test (p = ). Of the 77 Ia + patients, 43 were tested for CALLA; 36 were CALLA+ and 7 were CALLA- (Table 2). Thirty-four of the CALLA + patients and all 7 of the CALLA- patients entered complete remission. Figure 3 shows the disease-free survival for these 41 lo0 c.) Ia Months Fig. 2. Disease-free survival for 73 la+ and 10 HTA+ patients. The difference is statistically significant (p = ). IO Months Fig. 3. Disease-free survival for 41 Ia + patients who were also tested for CALLA. Within the Ia + group, the difference between CALLA + and CALLA - patients is not statistically significant.
7 IMMUNE MARKERS IN CHILDHOOD ALL 399 patients. Although with this small number of patients the results are not statistically significantly different within the Ia+ groups, these data are suggestive that CALLA positivity is a favorable prognostic factor. Patients with elevated WBC and those who are either older or very young have traditionally been considered to have an adverse prognoses.226 Table 3 shows the projected median duration of disease-free survival by WBC and age for our complete remitters in both the HTA+ and la+ groups. As expected, a high proportion of HTA + patients fall into the traditionally poor prognostic group, and our data show a trend toward worse prognosis that follows traditional guidelines. A proportional hazard regression model,23 has been used to ascertain the relative prognostic importance of the HTA as well as traditional factors. While neither age nor WBC are significant prognostic factors alone, when both factors are considered together (resulting in the four categories as shown in Table 3), the differences in outcome are statistically significant (p = 0.001). When the HTA factor is added to this model, the fit of the model is significantly improved (p = 0.014; using twice the difference in maximum log likelihood). Thus, even when age and initial WBC are accounted for in this fashion, HTA+ patients do much worse than Ia patients. Figure 4 shows the disease-free survival curves for Ia patients by age category and initial WBC. In contrast to the significant difference seen for the total group of 83 patients (p = using the log-rank test), the difference among the curves shown in Fig. 4 for the Ia patients is not statistically significant. However, there did appear to be a trend along traditional lines that may make it possible to identify a poor prognostic group within the Ia population. Identification of such a group by the use of cell surface marker as well as traditional prognostic factors will allow a more precise definition of subgroups. DISCUSSION The present studies confirm and extend previous observations that T-cell (HTA) ALL patients Table 3. Projected Median Duration in Months of Disease-Free Survival by WBC. Age. and Cell Surface Marker LowWBC Age 2-9 <2 or >9 Age 2-9 The number of patients is shown in parentheses. Low wsc means presenting white blood count 25,000/cumm and high WBC is >25,000/cumm. Ages are in years. tvalue of the median has not been reached, but the plateau begins at the stated time. High WBC <2 or >9 la+ >48t(36) >49 (17) 44(16) 19(4) HTA+ 15 (2) 9 (1) 1 1 (3) 5 (4) c) I Months Fig. 4. Disease-free survival for 73 Ia + patients by initial WBC and age category. (Curve A) Seventeen patients with WBC 25,000/cu mm and ages < 2 or > 9. (Curve B) Thirty-six patients with WBC /cumm and ages 2-9. (Curve C) Sixteen patients with WBC > /cumm and 2-9 yr. (Curve D) Four patients with WBC > /cumm and ages <2 or >9 yr. The difference among the curves is not statistically significantly different. respond poorly to current therapeutic regimens and indicate that serologic methods provide a means for prompt and reliable diagnosis. The HTA antisera define a distinct subpopulation of lymphocytes and is reactive with thymocytes, peripheral T cells, and T- cell leukemic blasts, but is unreactive with B lymphocytes and normal myeloid and erythroid cells. Although patients with leukemia identified as HTA in this series were also E-rosette positive, we and others have noted instances where leukemic cells were HTA and E-rosette negative.2729 We, therefore, do not routinely use the E-rosette test to define T-cell leukemias. The Ia antigen, in contrast, is found on lymphoblasts of approximately 80% of children with ALL, on normal B cells, monocytes, myeloid, and erythroid progenitor cells, and on a null cell subset destined to differentiate into B cells. 3 This antigen is serologically and biochemically distinct from HLA antigens and is analogous to the murine Ia antigens and other B-cell alloantigens, which have been shown to play a major role in the stimulation of the allogeneic mixed lymphocyte 303 From the standpoint of differential diagnosis, the Ia antiserum is able to confirm the diagnosis of T-cell ALL, since the Ia antigen is normally absent on T-cell surfaces. In contrast, most other forms of ALL and acute myelogenous leukemia possess the Ia antigen. Thus, the HTA and Ia antigens define reciprocal subsets of ALL. Moreover, we can further define the Ia subset with the CALLA antiserum; cells of patients with Ia+ ALL may be CALLA or CALLA. Patients whose lymphoblasts were CAL- LA- appeared to do poorly when compared with
8 400 SALLAN ET AL. CALLA+ patients; this finding is analogous to the experience of others.5 The relative prognostic importance of cell surface markers as compared to traditional clinical prognostic factors, such as age and WBC at the time of diagnosis, has been explored. It is apparent that much overlap exists between patients who are HTA, older, and have elevated WBCs. Clinical heterogeneity also exists within immunologically homogeneous patient groups. Treatment programs must be based on the most discriminating prognostic factors. For example, 3 of 1 1 HTA+ patients did not have elevated WBCs at the time of diagnosis, and 4 of 1 1 did not have radiographically apparent mediastinal masses. It must also be recognized that methods of immunologic classification will continue to improve. Indeed, subsets of HTA + patients have already been recognized, as have clinical and prognostic variability within such subsets Our multivariate analysis of the results, presented in Table 3, demonstrates that the combination of presenting ages and initial WBC has prognostic significance in the total patient group. In addition, HTA type has prognostic significance even when traditional clinical factors are controlled in the analysis. The overall prognostic value of age and WBC in our Ia patients using this treatment program is not statistically significant (Fig. 4). However, subgroups of Ia+ patients who have poorer prognoses may yet be identifled. These subgroups may be distinguished not only on the basis of clinical findings, but more specifically on the basis of immunologic markers. Therapeutic results must be viewed in the context of a particular treatment program. Future treatment programs must consider possible biologic differences in the leukemias, such as those manifested by immunologic markers, as well as traditional factors. Why is conventional therapy unable to maintain continuous complete remission in the HTA+ patients? Suboptimal chemotherapy may in part contribute to the failure of this group. Evaluation of chemotherapy regimens in experimental leukemia systems shows that drugs effective against thymusderived AKR leukemia are frequently different from those effective in conventional mouse lymphoid leukemia systems.34 Specifically, antimetabolites such as methotrexate and 6-mercaptopurine, both highly active in conventional, non-t-cell leukemia, are relatively inactive in the AKR system. On the other hand, cyclophosphamide and cytosine arabinoside are more active against T-cell leukemias than against the conventional models. Distribution and migration of the HTA lymphoblasts may be different from Ia lymphoblasts, resulting in sequestration of cells in extramedullary sites and escape from chemotherapy in the former group. Studies in mice demonstrated that purified T cells migrate to the skin and other soft tissues, whereas B cells invariably circulate and migrate into lymph nodes and spleen.35 This tropism would account for the more successful control of extramedullary disease in Ia leukemia and provide an explanation for the frequency of and sites for extramedullary relapse in the HTA population. In this treatment program 67% of the relapses in the HTA patients and 17% ofthe relapses in Ia patients were at extramedullary sites. With the exception of two explainable meningeal relapses (inadequate irradiation and presentation with preexisting nervous system involvement), the incidence of central nervous system relapse was 50% for HTA and 7% for Ia patients who relapsed. Three of the four testicular failures were in the HTA group. These patients relapses occurred early in the course of therapy, wheras the Ia patient s relapse occurred after elective cessation of chemotherapy. In part, these data are in accord with a previous report that suggested a temporally bimodal pattern of testicular relapse.36 In contrast to recent reports of an increased incidence of testicular relapse after cessation of therapy,339 we have found only one such patient. The generally unsuccessful treatment of T-cell leukemia and its pattern of early relapse suggest that the late testicular relapses reported by others occur mainly in patients with non-t-cell disease. The difference between our experience and that of others is probably due to differences in treatment programs. The major innovation in our program is the early and intensive use of adriamycin. Our results are of importance because they indicate that prophylactic gonadal irradiation may be unnecessary in Ia patients. Moreover, this further emphasizes that the course of leukemia must be viewed in the context of particular therapeutic programs, as well as that of cell surface markers. The precise cellular derivation of the Ia cells is unknown; however, the presence of the Ia antigen and the absence of T-cell antigens suggest that these leukemic cells may be derived from the B-cell lineage. The finding of intracytoplasmic 1gM in a significant percentage of non-t leukemia lymphobasts is further evidence for this hypothesis.#{176} 4 Since the Ia antigens are critical in the initiation of a mixed lymphocyte response and in the generation of cytotoxic T lymphocytes, the absence of these antigens on the HTA+ cells may also help to explain the poor prognosis of these patients. In summary, we have described leukemia-associated antigens, HTA, Ia and CALLA, and their
9 IMMUNE MARKERS IN CHILDHOOD ALL 401 distribution in a childhood leukemia population; HTA + (1 2%), Ia + (88%), and of those who are Ia +, 84% are CALLA+ and 16% CALLA-. We have confirmed the finding that patients with T-cell disease have a worse prognosis than non-t-cell patients in a large population receiving an identical treatment program. Current treatment protocols appear to be highly effective in the subset of non-t-cell patients who are CALLA +. Improved regimens are required for the treatment of HTA + patients and possibly for Ia+ CALLA-. patients as well. Immunologic characterization of distinct subsets of ALL such as these should allow for the refinement of treatment programs specific for each subset. ACKNOWLEDGMENT We are grateful to our fellows, residents, nurses, and technicians whose invaluable assistance has made this work possible. REFERENCES 1. Sallan SE, Camitta BM, Cassady JR. Nathan DG, Frei E III: intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: Clinical results. Blood 51: , George SL, Aur RJA, Mauer AM, Simone JV: A reappraisal of the results of stopping therapy in childhood leukemia. N EngI i Med 300: , Gee TS, Haghbin M, Dowling MD ir, Cunningham I, Middleman MP, Clarkson BD: Acute lymphoblastic leukemia in adults and children: Differences in response with similar therapeutic regimens. Cancer 37: , Tsukimoto I, Wong HY, Lampkin BC: Surface markers and prognostic factors in acute lymphoblastic leukemia. N Engl J Med 294: , Chessells im, Hardisty RM, Rapson NT, Greaves MF: Acute lymphoblastic leukaemia in children: Classification and prognosis. Lancet 2: , Borella, L, Sen L, Dow LW, Casper it: Cell differentiation antigens versus tumor-related antigens in childhood acute lymphoblastic leukemia (ALL). Clinical significance of leukemia markers, in Thierfelder 5, Rod H, Thiel E (eds): Haematologie und Bluttransfusion, vol 20. (Immunological Diagnosis of Leukemias and Lymphomas) Berlin, Springer-Verlag, 1977, pp Schlossman SF, Chess L, Humphreys RE, Strominger il: Distribution of Ia-like molecules on the surface of normal and leukemic human cells. Proc Natl Acad Sci USA 73: , Kadin ME, Billing Ri: B-lymphocyte antigens in the differential diagnosis of human neoplasia. Blood 51: , Fu SM, Winchester Ri, Kunkel HG: The occurrence of the HL-B alloantigens on the cells of unclassified acute lymphoblastic leukemias. J Exp Med 142: , Pesando i, Ritz i, Lazarus H, Baseman Costello 5, Sallan 5, Schlossman SF: Leukemia associated antigens in acute lymphoblastic leukemia. Blood 54: , 1979 Ii. Humphreys RE, McCune.1MM, Chess L, Herrman HC, Malenka Di, Mann DL, Parham P. Schlossman SF, Strominger JL: Isolation and immunologic characterization of a human B-lymphocyte-specific, cell surface antigen. i Exp Med 144:98-112, Chess LR, Evans R, Humphreys RE, Strominger JL, Schlossman SF: Inhibition of antibody dependent cellular cytotoxicity and immunoglobulin synthesis by an antiserum prepared against a human B cell Ia-like molecule. J Exp Med 144: , Winchester Ri, Ross GD, iarowski CI, Wang CY, Halper i, Broxmeyer HE: Expression of ia-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci USA 74: , Dritschilo A, Cassady ir, Camitta B, Jaffe N, Paed D, Furman L, Traggis D: The role of irradiation in central nervous system treatment and prophylaxis for acute lymphoblastic leukemia Cancer 37: , Furman L, Camitta BM, iaffe N, Paed D, Sallan SE, Cassady JR. Traggis D, Leavitt P, Nathan DG, Frei E III: Development ofan effective treatment program for childhood acute lymphocytic leukemia: A preliminary report. Med Pediatr Oncol 2: , Boyum A: Separation of leucocytes from blood and bone marrow. Scand i Clin Lab Invest 21 (Suppl 97): 51-76, Mills B, Sen L, Borella L: Reactivity of anti-human thymocyte serum with acute leukemic blasts. J Immunol 115: , Greaves MF, Janossy G: Anti-human T-cell SERA, in Bloom B, David J (eds): Methods in Cell Mediated and Tumor Immunity. New York, Academic, 1976, p Anderson ik, Metzgar RS: Detection and partial characterization of human T and B-lymphocyte membrane antigens with antisera to HSB and SB cell lines. i Immunol 120: , Foley GE, Lazarus H, Farber 5, Uzman BG, Boone BA, McCarthy RE: Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18: , Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. i Am Stat Assoc 53: , Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto i, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br i Cancer 35:1-39, Cox DR: Regression methods and life tables (with discussion). i R Stat Soc 34: , Till MM, Hardisty RM, Pike MC: Long survival in acute leukemia. Lancet 1: , Simone iv, Verzosa MS, Rudy JA: Initial features and prognosis in 363 children with acute lymphoblastic leukemia. Cancer 36: , Heideman RL, Falletta im, Mukhopadhyay N, Fernbach Di: Lymphocytic leukemia in children: Prognostic significance of clinical and laboratory findings at time of diagnosis. i Pediatr. 92: , Borella L, Casper it, Lauer Si: Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse. Blood 54:64-71, Brouct JC, Valensi F, Daniel MT. Flandrin G, Preud homme il, Seligmann M: Immunological classification of acute lymphoblastic leukaemias: Evaluation of its clinical significance in a hundred patients. Br i Haematol 33: , Melvin 5: Comparison of techniques for detecting T-cell acute lymphoblastic leukemia. Blood 54: , I Shreffler DC, David CS: The H-2 histocompatibility complex and the I immune response region: Genetic variation, function and organization. Adv Immunol 20: , Moller G: One non-specific signal triggers B-lymphocytes. Transplant Rev 23: , Reinherz EL, Nadler LM, Sallan SE, Schlossman SF:
10 402 SALLAN ETAL. Subset derivation of T-cell acute lymphoblastic leukemia in man. i Clin Invest 64: , Weinstein Hi, Vance ZB, Jaffe N, Buell D, Cassady ir: Improved prognosis for patients with mediastinal lymphoblastic lymphoma. Blood 53: , Frei E III, Schabel FM ir, Goldin A: Comparative chemotherapy of AKR lymphoma and human hematological neoplasia. Cancer Res 34: , Bhan AK, Reinisch CL, Levey RH: 1-cell migration into allografts. i Exp Med 141: , Nesbit M, Robinson L, Ortega J, Sather HN, Donaldson M, Hammond D: Testicular relapse in childhood acute lymphoblastic leukemia: Association with pretreatment patient characteristics and treatment. Cancer (in press) 37. Kuo T, Tschiang 1, Chu JYC: Testicular relapse in child- hood acute lymphocytic leukemia during bone marrow remission. Cancer 38: , Medial Research Council s Working Party on Leukaemia: Testicular disease in acute lymphoblastic leukaemia in childhood. BrMedi 1: , Simone iv, Aur RJA, Hustu Ho, Verzosa MS, Pinkel D: Three to ten years after cessation of therapy in children with leukemia. Cancer 42: , Vogler LB. Christ WM, Bockman DE, Pearl ER, Lawton AR, Cooper MD: Pre-B-cell leukemia: A new phenotype of childhood lymphoblastic leukemia. N Engl i Med 298:872, Brouet JC, Preud homme il, Penit C, Valensi F, Rouget P. Seligman M: Acute lymphoblastic leukemia with pre-b-cell characteristics. Blood 54: , 1979
LOW INCIDENCE OF CNS RELAPSE WITH CRANIAL RADIOTHERAPY AND INTRATHECAL METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA
Original Articles LOW INCIDENCE OF CNS RELAPSE WITH CRANIAL RADIOTHERAPY AND INTRATHECAL METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA N.S. Raje, S.J. Vaidya, G. Kapoor, S.K. Pai, C.N. Nair, P.A. Kurkure,
More informationResults of LSA2-L, Therapy in Children with High-Risk Acute Lyrnphoblastic Leukemia and Non-Hodgkin's Lymphoma *
Haematology and Blood Transfusion Vol. 28 Modem Trends in Human Leukemia V Edited by Neth, Gallo, Greaves, Moore, Winkler @ Springer-Verlag Berlin Heidelberg 1983 Results of LSA2-L, Therapy in Children
More information1 Introduction. 1.1 Cancer. Introduction
Introduction 1 1.1 Cancer 1 Introduction Cancer is the most precarious disease characterized by uncontrolled proliferation of cells without any physiological demands of the organism. Cancer may be defined
More informationIsolated Eye Relapse of Acute Lymphocy tic Leukemia during Intensification Therapy with Vincristine and Prednisolone
Jpn. J. Pediatr. Hematol. 2: 406-410, 1988 Case Report Isolated Eye Relapse of Acute Lymphocy tic Leukemia during Intensification Therapy with Vincristine and Prednisolone Fumio BEssHo,*1 Hiroshi KINUMAKI,*2
More informationDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, 830, Japan. (Received for publication January 24, 1977)
THE KURUME MEDICAL JOURNAL Vol.24, No.1, p.35-41, 1977 LEUKEMIA IN CHILDREN THE CLINICAL AND THERAPEUTIC STUDIES OF 100 CASES TAKASHI YOKOYAMA, YASUHIKO HIYOSHI AND KINSUKE NAKAGAWA Department of Pediatrics
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationLaboratory Correlates and Prognostic Significance of Granular Acute Lymphoblastic Leukemia in Children A Pediatric Oncology Group Study
HEMATOPATHQLOGY AND LABORATORY HEMATOLOGY Original Article Laboratory Correlates and Prognostic Significance of Granular Acute Lymphoblastic Leukemia in Children A Pediatric Oncology Group Study LIZARDO
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationLymphoid Malignancies of B Cell Origin
A Unique Cell Surface Antigen dentifying Lymphoid Malignancies of B Cell Origin LEE M. NADLER, JEROME RTZ, RUSSELL HARDY, JOHN M. PESANDO, and STUART F. SCHLOSSMAN, Division of Tumor mmunology, Sidney
More informationCombination Therapy for Childhood Acute Lymphocytic Leukemia
Rhomes J. A. Aur, MD*, Kwesi Sackey, MB ChB, Rajeh S. Sabbah, MD, Samira Rifai, MD, J. Trenholme Griffin, MD, Mustapha Ghandour, MD, Flynn Warren, MS *Head, Division of Pediatric Oncology, Department of
More informationInduction of Human B Cell Antigens in Non-T
Induction of Human B Cell Antigens in Non-T Cell Acute Lymphoblastic Leukemia LEE M. NADLER, JEROME RITZ, MICHAEL P. BATES, EDWARD K. PARK, KENNETH C. ANDERSON, STEPHEN E. SALLAN, and STUART F. SCHLOSSMAN,
More informationSaturday 4 April 1981
Saturday 4 April 1981 DIFFERENCES IN PROGNOSIS FOR BOYS AND GIRLS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA HARLAND SATHER Department of Family and Preventive Medicine, University of Southern California, Los
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationPrognostic Factors in Adult Acute Lyrnphoblastic Leukemia
Prognostic Factors in Adult Acute Lyrnphoblastic Leukemia Lister. T.A.'. Roberts. M. M.', Brearley, R. L.2, Cullen, M.H.', Greaves. M. F.' Introduction The introduction of three and four drug combination
More informationMethods. G. R. Pilkington, N. Kraft, V. Murdolo, G. T. H. Lee, S. V. Hunter, R. C. Atkins, and D.G.Jose 2
Serological Typing of Acute Leukemia Using the Monoclonal Antibodies PHM 1, 2, 3, 6, CIKM5, and the Rabbit Antisera RARC2a (Ad) and RAALLP50 1 G. R. Pilkington, N. Kraft, V. Murdolo, G. T. H. Lee, S. V.
More informationManipulation of T Cells in the Thnsplant Inoculum
International Journal of Cell Cloning 4: 122-126 Suppl 1 (1986) Manipulation of T Cells in the Thnsplant Inoculum J. Kersey Bone Marrow Transplantation Program, University of Minnesota, Minneapolis, MN,
More informationB Cell Origin of Non-T Cell Acute Lymphoblastic Leukemia A Model for Discrete Stages of Neoplastic and Normal Pre-B Cell Differentiation
B Cell Origin of Non-T Cell Acute Lymphoblastic Leukemia A Model for Discrete Stages of Neoplastic and Normal Pre-B Cell Differentiation Lee M. Nadler, Stanley J. Korsmeyer, Kenneth C. Anderson, Andrew
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationPediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand
Pediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand Piya Rujkijyanont MD*, Suphathida Kaewinsang MD*, Chalinee Monsereenusorn
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationBEFORE THE INCORPORATION of prophylactic CNS
Improved Survival of Children With Isolated CNS Relapse of Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study By A. Kim Ritchey, Brad H. Pollock, Stephen J. Lauer, Yvonne Andejeski, and George
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationA lthough central nervous system (CNS) prophylaxis in patients with ALL has
Original Article Central nervous system relapse prophylaxis in acute lymphoblastic leukemia (ALL) intrathecal chemotherapy with and without cranial irradiation Ahmad Tamaddoni (MD) 1 Hassan Mahmodi Nesheli
More informationSTUDY OF PROGNOSIS IN ACUTE MYELOID LEUKEMIAS (AML) BY CLUSTER ANALYSIS
original papers Haematologica 1994; 79:233-240 STUDY OF PROGNOSIS IN ACUTE MYELOID LEUKEMIAS (AML) BY CLUSTER ANALYSIS Gian Matteo Rigolin, Franca Fagioli, Romedio Spanedda, Gianluigi Scapoli, Francesco
More informationCME/SAM. Mixed Phenotype Acute Leukemia
AJCP / Original Article Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria Olga K. Weinberg,
More informationImproved Results in Treatment of Acute Myelogenous Leukemia in Children - Report of the German Cooperative AML Study BFM-78 *
Haematology and Blood Transfusion Vol. 28 Modem Trends in Human Leukemia V Edited by Neth, Gallo, Greaves, Moore, Winkler 0 Springer-Verlag Berlin Heidelberg 1983 Improved Results in Treatment of Acute
More informationImproved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant Jeong A Park 1,
More informationWedge biopsies of the testis were obtained from 37 boys with ALL. Repeat biopsies were obtained from
J Clin Pathol 1986;39:1236-1240 Terminal transferase positive cells in testicular biopsy specimens from boys with acute lymphoblastic leukaemia J M CHESSELLS,* J R PINCOTT,* W DANIELS-LAKE*t From the *Departments
More informationPROGNOSTIC FACTOR ANALYSIS IN ADULT ACUTE LEUKEMIA DURING THE PERIOD OF 1973 TO 1983
Keio Journal of Medicine 34: 17-23, 1985 PROGNOSTIC FACTOR ANALYSIS IN ADULT ACUTE LEUKEMIA DURING THE PERIOD OF 1973 TO 1983 HAYATO MIYACHI, YUZURU TAKEMURA, KEISUKE TOYAMA and TOSHIAKI HIGASHI*, Department
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationOrgan irradiation and combination chemotherapy in treatment of acute lymphocytic leukaemia in children
Archives of Disease in Childhood, 1975, 50, 685. Organ irradiation and combination chemotherapy in treatment of acute lymphocytic leukaemia in children P. LANZKOWSKY, A. SHENDE, I. ARAL, and G. SALUJA
More informationPrognostic significance of leukopenia in childhood acute lymphoblastic leukemia
ONCOLOGY LETTERS 7: 1169-1174, 2014 Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia YUSUKE SHIOZAWA 1, JUNKO TAKITA 1,2, MOTOHIRO KATO 3, MANABU SOTOMATSU 4, KATSUYOSHI
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationDetermining Prognosis in Childhood Acute Lymphoblastic Leukemia by Phytohemagglutinin (PHA) Stimulated Lymphocytes
Determining Prognosis in Childhood Acute Lymphoblastic Leukemia by Phytohemagglutinin (PHA) Stimulated Lymphocytes Timur Sumer, MD* and Lucius F. Sinks, MD *Assistant Professor of Pediatrics, College of
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationCorrelation of Sex and Remission of Acute Lymphoblastic Leukemia-L1 (ALL-L1) in Children
International Journal of Clinical and Experimental Medical Sciences 2015; 1(2): 11-15 Published online July 6, 2015 (http://www.sciencepublishinggroup.com/j/ijcems) doi: 10.11648/j.ijcems.20150102.12 Correlation
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationJPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep Original Articles
JPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep. 2003 Original Articles Outcome of Adult Acute Lymphoblastic Leukemia: a Single Center Experience M. Usman, I. Burney*, A. Nasim*, S. N.
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationH Schroeder 1, G Gustafsson 2, UM Saarinen-Pihkala 3, A Glomstein 4, G Jonmundsson 5, K Nysom 6, O Ringdén 7 and L Mellander 8.
Bone Marrow Transplantation, (1999) 23, 555 560 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Allogeneic bone marrow transplantation in second remission
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationColony-forming ability of marrow from patients receiving immunotherapy during chemotherapyinduced
J. clin. Path., 1977, 3, 7-75 Colony-forming ability of marrow from patients receiving immunotherapy during chemotherapyinduced remission in acute myeloid leukaemia M. Y. GORDON1, R. L. POWLES2, ND I.
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationS efforts have been made to identify prognostic
INITIAL FEATURES AND PROGNOSIS IN 363 CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA JOSEPH V. SIMONE, MD,* MANUEL S. VERZOSA, MD,+ AND JUDITH A. RUDY, RN~ The relationship of a variety of initial features and
More informationI and radiation therapy have led to an improvement
NON-HODGKIN S LYMPHOMA IN CHILDREN Correlation of CNS Disease With Initial Presentation. JOHN J. HUTTER, JR., MD,* BLAISE E. FAVARA, MD,+ MICHAEL NELSON, MD (MAJOR),$ AND CHARLENE P. HOLTON, MD The clinical
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationIrinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Biondi A, Schrappe M, De Lorenzo P, et al.
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress WHAT IS THE BEST PROTOCOL FOR CANINE LYMPHOMA? Antony S. Moore, M.V.Sc., Dipl. A.C.V.I.M. (Oncology) Veterinary
More informationEarly Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia
Early Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia Martha Arellano, MD 1 ; Suchita Pakkala, MD 1 ; Amelia Langston, MD 1 ; Mourad Tighiouart,
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationComplete Remissions in Metastatic Breast Cancer Treated with Combination Drug Therapy
Complete Remissions in Metastatic Breast Cancer Treated with Combination Drug Therapy SEWA S. LEGHA, M.D.; AMAN U. BUZDAR, M.D.; TERRY L SMITH, B.S.; GABRIEL N. HORTOBAGYI, M.D.; KENNETH D. SWENERTON,
More informationImatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationSurvival from acute non-lymphocytic leukaemia, : a population based study
Archives of Disease in Childhood 1994; 70: 219-223 Childhood Cancer Research Group, University of Oxford, Department of Paediatrics, 57 Woodstock Road, Oxford OX2 6HJ C A Stiller E M Eatock Correspondence
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationVUmc Basispresentatie
Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationSylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.
Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationCHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in of Childhood Leukemia with Down Syndrome Analysis Concept Proposal Working Group and Investigators Genetics Working Group & Chronic Disease Working
More informationBESIDES their beneficial effect in retarding
BESIDES their beneficial effect in retarding or arresting the growth of certain types of neoplasms, a number of anticancer drugs may cause impairment of antibody synthesis and cell-mediated immunity. These
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationNatural history of insect ir, g allergy: Relationship of severity of sym oms of initial sting anaphylaxis to re-sting rea ions
Natural history of insect ir, g allergy: Relationship of severity of sym oms of initial sting anaphylaxis to re-sting rea ions Robert E. Reisman, MD Buffalo, N.Y. To examine the postulate that the nature
More informationFrench American British (FAB) morphological classification of childhood lymphoblastic leukaemia
J Clin Pathol 1986;39:998-1002 French American British (FAB) morphological classification of childhood lymphoblastic leukaemia and its clinical importance J S LILLEYMAN,* I M HANN,t R F STEVENS,: 0 B EDEN,
More informationBACKGROUND AND RATIONALE
SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of
More informationCase Report T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
Case Reports in Hematology, Article ID 359158, 4 pages http://dx.doi.org/10.1155/2014/359158 Case Report T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission Lauren Elreda, 1
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationThe tenth acute myeloid leukemia (AML) trial conducted
CLINICL UPDTE U p d a t e s o n s t u d y f i n d i n g s i n e s s e n t i a l t h e r a p e u t i c a r e a s o f c a n c e r a n d b l o o d d i s o r d e r s Long-term Results of the MRC ML1 Trial
More informationPAPERS AND ORIGINALS
BRITISH MEDICAL JOURNAL 16 SEPTEMBER 1978 787 PAPERS AND ORIGINALS Effects of varying radiation schedule, cyclophosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia Report to
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationGetting to the root of Cancer
Cancer Stem Cells: Getting to the root of Cancer Dominique Bonnet, Ph.D Senior Group Leader, Haematopoietic Stem Cell Laboratory Cancer Research UK, London Research Institute Venice, Sept 2009 Overview
More informationulation of NK cells that retain the capability of expressing the HNK-1 differentiation antigen. Children with the Chediak-Higashi (CH)' syndrome,
RAPID PUBLICATIONS Natural Killer (HNK-1l) Cells in Chediak-Higashi Patients Are Present in Numbers but Are Abnormal in Function and Morphology TORu ABO, JOHN C. RODER, WATARU ABO, MAX D. COOPER, and CHARLES
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationSeizure remission in adults with long-standing intractable epilepsy: An extended follow-up
Epilepsy Research (2010) xxx, xxx xxx journal homepage: www.elsevier.com/locate/epilepsyres Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up Hyunmi Choi a,, Gary
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
V O L U M E 2 6 N U M B E R 1 8 J U N E 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationOutcome of adult patients with acute
Original Article Singapore Med J 2011; 52(5) 370 Outcome of adult patients with acute lymphoblastic leukaemia receiving the MRC UKALL XII protocol: a tertiary care centre experience Shaikh M U, Ali N,
More informationBiol Blood Marrow Transplant 19 (2013) 255e259
Biol Blood Marrow Transplant 19 (2013) 255e259 Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic
More informationClinical profile of ITP in Children: A single center study
Clinical profile of ITP in Children: A single center study Dr.Ramadan Allalous 1,Dr Fathia Alriani 1, Dr Amna Rayani 2. 1Tripoli ' s Medical center,medical Faculty, Tripoli University 2Tripoli Children
More informationIn Vitro Growth of Erythropoietic Progenitor Cells in Long-%rm Remission of Acute Leukemia
International Journal of Cell Cloning 4: 186-191 (1986) In Vitro Growth of Erythropoietic Progenitor Cells in Long-%rm Remission of Acute Leukemia C. Peschel, G. Konwalinka, D. Geissler, H. Bmunsteiner
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationIsolated Testicular Relapse in Acute Lymphoblastic Leukemia - Effective Treatment with the Modified CCG-112 Protocol
Original Article Isolated Testicular Relapse in Acute Lymphoblastic Leukemia - Effective Treatment with the Modified CCG-112 Protocol Goyal Shama, Bhagwat Roshni, Pai Suresh K, Kurkure Purna A, Nair Chandrika
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More information